Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant in ER+/HER2+ Breast Cancer Brain Metastasis
NCT04334330Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2020
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of palbociclib, trastuzumab, pyrotinib, fulvestrant in breast cancer, sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04334330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04334330.